Parx Materials N.V. (Euronext Access: MLPRX) develops and markets biocide-free antimicrobial and antifouling polymer technologies inspired by the human immune system, incorporating a trace element to prevent bacterial adhesion, biofilm formation, viruses, moulds and fouling on plastic surfaces without migration, leaching or inducing resistance. The company offers Saniconcentrate masterbatches and Passive Action Polymer Technology for integration into plastics, serving applications in food contact and packaging; medical implants and devices; textiles; pipes, drainages and water infrastructure; anti-fouling surfaces; consumer goods; aquaculture; and hygiene products to inhibit microbial growth while maintaining material recyclability and safety for humans, animals and the environment. Founded in 2012 and headquartered in Rotterdam, Netherlands, with production scaling in Italy and operations extending to Europe including Ravenna, the company targets industries requiring hygienic, durable and sustainable materials. In July 2024, GCP Technology AS, a Norwegian technology firm backed by investors, acquired nearly 57% of shares from founders Michael van der Jagt and Michele Fiori, who remain involved; GCP also took over partner ZincIn AS to advance technology development. In December 2024, Parx acquired initial production equipment in Italy for scalable manufacturing, supported by GCP, to meet demand in strategic sectors like aquaculture and food packaging while transitioning to integrated processes.